Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
BENICAR HCT 40mg/12.5mg |
| Manufacturer |
|
Daiichi-Sankyo |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker + diuretic. |
| Generic Name |
|
Olmesartan medoxomil 40mg, hydrochlorothiazide 12.5mg; tabs. |
| Also |
• BENICAR HCT 20mg/12.5mg
• BENICAR HCT 40mg/25mg
|
| Indications |
|
Hypertension. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Not for initial therapy. May be substituted for titrated components. Individualize. ≥18yrs: BP not controlled on olmesartan or HCTZ alone: one tab once daily; may titrate at 2–4 week intervals; usual max 40mg/25mg once daily. Severe renal impairment (CrCl ≤ 30mL/min): not recommended. Volume depleted: reduce dose. |
| Contraindications |
|
Anuria. Sulfonamide allergy. Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct salt/volume depletion before starting, or monitor closely. Renal or hepatic dysfunction. Renal artery stenosis. Severe CHF. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Monitor electrolytes. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Digitalis, lithium toxicity. Adjust antidiabetic, antigout medications. Hyperkalemia with K+ supplements, K+ sparing diuretics, or K+ containing salt substitutes. ACTH, amphotericin B, corticosteroids increase hypokalemia risk. Orthostatic hypotension potentiated by alcohol, CNS depressants. Antagonized by NSAIDs. Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May antagonize norepinephrine. May interfere with parathyroid tests. |
| Adverse Reactions |
|
Dizziness, infection, hyperuricemia, nausea, back pain, weakness, orthostatic hypotension, electrolyte disturbances, rash, adverse lipid values, rhabdomyolysis (rare). |
| How Supplied |
|
Tabs—30, 90, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
